Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Arch Ventures
Deal Size : $216.0 million
Deal Type : Series A Financing
BMS-backed Dispatch Unveils with $216M, Carl June as Cofounder
Details : The proceeds from the financing will be used to advance the company’s therapeutic CAR‑T cell candidates into first-in-human clinical studies for the traetment of cancer.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 23, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Arch Ventures
Deal Size : $216.0 million
Deal Type : Series A Financing